Emcure Pharma Q2 FY27 results: Net profit jumps 34% YoY; domestic business revenue increases to ₹1,155 crore

The pharma major’s revenue from operations grew 24% to ₹2,820 crore in the September quarter, as against ₹2,270 crore registered in the year-ago period.

Emcure’s operating profit, also known as earnings before interest, taxes, depreciation, and amortisation (EBITDA), jumped 24% to ₹588 crore as compared to ₹475 crore in the corresponding quarter of the previous fiscal year.

Its EBITDA margin remained almost flat at 20.84% in contrast to 20.9% in Q2 FY26.

“Q2 was another strong quarter for Emcure, with broad-based growth in revenue, profitability and earnings. We expect business momentum to sustain into H2FY27,” said Satish Mehta, Chairman, Managing Director and CEO, Emcure Pharmaceuticals.

The company in its investors’ presentation said that it expects continued growth over the full year as Emcure’s strengthened team and portfolio gain traction.

Emcure Pharma’s domestic business revenue jumped 12% YoY to ₹1,155.3 crore in Q2 FY27. Its international business revenue increased 34.5% annually to ₹1,665.2 crore in the reporting quarter.

The growth in domestic business was led by the women’s health franchise, cardio-metabolics and the CNS range, supported by improved traction in Poviztra. However, for the international segment, growth was broad-based across Europe, Canada and the rest of the world, driven by continued expansion of the base business and new launches.

In Q2 FY27, the company invested ₹111 crore in research and development (R&D), accounting for around 4% of its revenue. Its net debt stood at ₹1,317.1 crore as of September 30, 2026.

For half a year (H1 FY27), the company’s net profit jumped to ₹620 crore as compared to ₹450 crore on a YoY basis, marking a growth of 38%. Its revenue from operations for H1 FY27 increased 23.5% to ₹5,401 crore as against ₹4,370 crore in H1 FY26.

Emcure Pharma share price trends

Following the earnings, Emcure Pharmaceuticals shares were trading at ₹1,973.60 apiece on the National Stock Exchange, gaining 4.78%. The stock has rallied 7.3% to touch an intraday high of ₹2,021 per share.

From the beginning of the year, Emcure Pharma shares have zoomed 43%. Over a month’s time, the stock has jumped 3%, while for a six-month period, it has surged 12%.

Shares of the firm had hit a 52-week high of ₹2,100.70 on September 18, 2026, and a 52-week low of ₹1,306.50 on November 4, 2025.

According to NSE data, as of November 3, 2026, Emcure Pharma has a total market capitalisation of ₹38,238.08 crore.